Ibuprofen

  • TRADE NAMES: Act-3; Actiprofen; Advil (Wyeth); Anco; Apsifen; Brufen; Ebufac; Genpril; Haltran; Lidifen; Medipren; Midol 220; Motrin (McNeil); Nuprin; Pamprin; Profen; Proflex; Rufen; Tabalom; Trendar; Urem; Vicoprofen (AbbVie)
  • INDICATIONS: Arthritis, pain
  • CLASS: Non-steroidal anti-inflammatory (NSAID)
  • HALF-LIFE: 2–4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aspirin, Ciprofibrate, Diuretics, Methotrexate, Methyl salicylate, NSAIDs, Oxycodone hydrochloride, Salicylates, Tacrine, Tacrolimus, Urokinase, Voriconazole

PREGNANCY CATEGORY: D
category C prior to 30 weeks gestation; category D starting at 30 weeks gestation

Under investigation for treating COVID-19

See adverse reactions attributed to class:

Non-steroidal anti-inflammatory (NSAID)

NSAIDs may cause an increased risk of serious cardiovascular and gastrointestinal adverse events, which can be fatal. This risk may increase with duration of use.

Acute generalized exanthematous pustulosis (AGEP) 

(2014): Blake T+, Case Rep Dermatol 6(1), 29

(2014): Grando LR+, An Bras Dermatol 89(5), 75850%

(2013): Arochena L+, Ann Allergy Asthma Immunol 110(5), 386

(2009): Rastogi S+, Br J Oral Maxillofac Surg 47 (2), 132

(2004): Yesudian PD+, Int J Dermatol 43(3), 208

Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock) <1%

(2014): Faria E+, J Investig Allergol Clin Immunol 24(1), 4025%

(2000): Takahama H+, J Dermatol 27, 337

(1998): Menendez R+, Ann Allergy Asthma Immunol 80, 225

(1985): J Rheumatol 12, 13

(1979): Finch WR+, JAMA 241, 2616

Angioedema <1%

(2011): Cimbollek S+, J Investig Allergol Clin Immunol 21(6), 488

(2011): Dona I+, Allergy 66(11), 1428

(2011): Kasemsarn P+, J Drugs Dermatol 10(10), 1160

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1987): Shelley ED+, J Am Acad Dermatol 17, 1057

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern RS+, JAMA 252, 1433

(1982): Bailin PL+, Clinics in Rheumatic Diseases WB Saunders 8, 493 (passim)

Bullous dermatosis <1%

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1988): Laing VB+, J Am Acad Dermatol 19, 91

(1984): Stern R+, JAMA 252, 1433

Bullous pemphigoid / pemphigoid 

(1993): Fellner MJ, Clin Dermatol 11, 515 [REVIEW]

(1981): Pompeova L, Cesk Dermatol (Czech) 56, 256

Dermatitis <1%

(2015): Bello AE+, Curr Med Res Opin 31(3), 3974% (with famotidine)

(2014): Yu Q+, Curr Med Res Opin 30(9), 1863 (1 case)

(1993): Ophaswongse S+, Contact Dermatitis 29, 57 [REVIEW]

(1986): Veronesi S+, Contact Dermatitis 15, 103

(1985): Valsecchi R+, Contact Dermatitis 12, 286

Diaphoresis 

(1974): Regalado RG+, J Int Med Res 2, 115

DRESS syndrome 

(2016): Koca T+, Indian Pediatr 53(8), 745

(2016): Silva SA+, Rev Assoc Med Bras 62(3), 227 [REVIEW]

(2012): Wongkitisophon P+, Acta Derm Venereol 92(2), 200 [REVIEW]4%

(2001): Descamps V+, Arch Dermatol 137, 301

Eczema 

(1986): Veronesi S+, Contact Dermatitis 15, 103

Embolia cutis medicamentosa (Nicolau syndrome) 

(2003): Reding EL+, J Am Acad Dermatol 48(3), 472 (passim)

(2001): Corazza M+, J Eur Acad Dermatol Venereol 15(6), 585

Erythema multiforme <1%

(2014): Mokhtari F+, J Res Med Sci 19(8), 720 [REVIEW]13%

(2013): Desai NC+, J Pediatr Adolesc Gynecol 26(1), 65 (minor)

(2012): Alonso-Llamazares A+, J Investig Allergol Clin Immunol 22(5), 376

(2007): Dore J+, J Burn Care Res 28(6), 865

(1995): Lesko SM+, JAMA 273, 929

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 186 (passim)

(1985): J Rheumatol 12, 13

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern R+, JAMA 252, 1433

(1978): Sternlieb P+, N Y State J Med 78, 1239

Erythema nodosum <5%

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

Exanthems 

(2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 53

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1980): Shoenfeld Y+, JAMA 244, 547

(1979): Finch WR+, JAMA 241, 2616

(1978): Sonnenblick M+, BMJ 1, 619

(1975): Blechman WJ+, JAMA 233, 3363%

(1974): Regalado RG+, J Int Med Res 2, 115<1%

(1973): Mills SB+, BMJ 4, 82

Excoriations 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3976% (with famotidine)

Exfoliative dermatitis 

(2011): Hydzik P+, Przegl Lek 68(8), 503 (with acetaminophen and macrolide antibiotic)

Fixed eruption <1%

  • Fixed eruption from ibuprofen

(2017): Garcia D+, Expert Rev Clin Pharmacol 10(7), 717 [REVIEW] (passim)

(2012): Chen JF+, Can Fam Physician 58(6), 659

(2012): Hanafusa T+, Eur J Dermatol 22(5), 680

(2012): Koshelev MV+, Dermatol Online J 18(11)

(2007): Fischer G, J Reprod Med 52(2), 81 (2 cases) (vulva)

(2006): Alvarez Santullano CV+, Allergol Immunopathol (Madr) 34(6), 280 (1 case)

(2003): Al Aboud K+, J Drugs Dermatol 2(6), 658

(2001): Diaz Jara M+, Pediatr Dermatol 18, 66

(1998): Mahboob A+, Int J Dermatol 37, 833

(1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 186 (passim)

(1991): Kuligowski ME+, Contact Dermatitis 25, 259

(1990): Bharija SC+, Dermatologica 181, 237

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Kanwar AJ+, J Dermatol 11, 383

(1984): Stern R+, JAMA 252, 1433

Henoch–Schönlein purpura 

(2016): Seong CL+, Indian J Pharmacol 48(6), 739

Herpes zoster 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3974% (with famotidine)

Hot flashes / hot flushes <1%

(package insert)

Hypersensitivity 

(2016): King G+, Eur Arch Paediatr Dent 17(4), 277

(2010): Nanau RM+, Transl Res 155 (6), 275

(2006): Mou SS+, J Rheumatol 33(1), 171

(2001): McMahon AD+, J Clin Epidemiol 54(12), 1271

(1981): Ruppert GB+, South Med J 74, 241

Lupus erythematosus 

(1993): Vigouroux C+, Rev Med Interne (French) 14(9), 856

(1985): J Rheumatol 12, 13

(1980): Bar-Sela S+, J Rheumatol 7, 379

(1978): Pereyo-Torrellas N, Arch Dermatol 114, 1097

(1978): Sonnenblick M+, BMJ 1, 619 (exacerbation)

Pemphigus 

(1988): Laing VB+, J Am Acad Dermatol 19, 91

Peripheral edema (see also edema) 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3975% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Photosensitivity 

(1994): Berger TG+, Arch Dermatol 130, 609 (5 cases) (in patients with HIV)

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1992): Bergner T+, J Am Acad Dermatol 26, 114

(1990): Bergner T+, J Allergy Clin Immunol 85, 177

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1982): Bailin PL+, Clinics in Rheumatic Diseases WB Saunders 8, 493

Pruritus (itching) <5%

(2018): Lewis F+, Clin Pharmacol Drug Dev Jan, Epub ahead of print (1 case) (from topical)

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 186 (passim)

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1979): Finch WR+, JAMA 241, 2616

(1975): Blechman WJ+, JAMA 233, 3362%

Pseudolymphoma 

(2001): Werth V, Dermatol Online J 7(1)

Psoriasis 

(palms)

(1986): Ben-Chetrit E+, Cutis 38, 45 (exacerbation)

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

Purpura 

(1969): Ward T, BMJ 4, 430

Rash >10%

(2018): Lewis F+, Clin Pharmacol Drug Dev Jan, Epub ahead of print (1 case) (from topical)

(2015): Bello AE+, Curr Med Res Opin 31(3), 3974% (with famotidine)

(1974): Regalado RG+, J Int Med Res 2, 115

Stevens-Johnson syndrome <1%

(2021): Gui MZ+, Transl Pediatr 10(6), 1737-1742 (1 case / female)Pediatric

(2018): Fakoya AOJ+, Open Access Maced J Med Sci 6(4), 730 [REVIEW]

(2017): Arantes LB+, An Bras Dermatol 92(5), 6615%

(2016): Belver MT+, Allergol Immunopathol (Madr) 44(1), 83 [REVIEW]Pediatric

(2014): Grando LR+, An Bras Dermatol 89(5), 7588%

(2013): Pliskow S, J Reprod Med 58(7-8), 354Pediatric

(2012): Alonso-Llamazares A+, J Investig Allergol Clin Immunol 22(5), 376

(2012): Bang D+, Pharmacoepidemiol Drug Saf 21(4), 38417%

(2009): Rijal A+, Indian J Dermatol Venereol Leprol 75(6), 613

(2007): Dore J+, J Burn Care Res 28(6), 865

(2007): Neuman M+, Transl Res 149(5), 254

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1978): Sternlieb P+, N Y State J Med 78, 1239

Thrombocytopenic purpura 

(2016): Benmoussa J+, Am J Emerg Med 34(5), 942.e5

Toxic epidermal necrolysis (Lyell's syndrome) <1%

(2017): Arantes LB+, An Bras Dermatol 92(5), 6615%

(2016): Belver MT+, Allergol Immunopathol (Madr) 44(1), 83 [REVIEW]Pediatric

(2014): Grando LR+, An Bras Dermatol 89(5), 7586%

(2014): Kim HY+, Yonsei Med J 55(3), 834Pediatric

(2013): Pliskow S, J Reprod Med 58(7-8), 354Pediatric

(2009): Rijal A+, Indian J Dermatol Venereol Leprol 75(6), 613

(2007): Dore J+, J Burn Care Res 28(6), 865

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1980): Sternlieb P+, Ann Intern Med 92, 570

Urticaria / hives >10%

(2016): Trautmann A+, J Allergy Clin Immunol Pract 4(6), 1205

(2011): Cimbollek S+, J Investig Allergol Clin Immunol 21(6), 488

(2006): Prado J+, Sao Paulo Med J 124(3), 135Pediatric

(2001): Diaz Jara M+, Pediatr Dermatol 18, 66

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1987): Shelley ED+, J Am Acad Dermatol 17, 1057

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern RS+, JAMA 252, 1433

(1982): Bailin PL+, Clinics in Rheumatic Diseases WB Saunders 8, 493 (passim)

(1975): Blechman WJ+, JAMA 233, 336<1%

Vasculitis (angiitis) / cutaneous vasculitis (angiitis) 

(2001): Davidson KA+, Cutis 67, 303 (bullous leukocytoclastic)

(1996): Peters F+, J Rheumatol 23, 2008

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

(1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 186 (passim)

(1985): Bigby M+, J Am Acad Dermatol 12, 866 [REVIEW]

(1984): Stern R+, JAMA 252, 1433

(1982): Labbe A+, Ann Dermatol Venereol (French) 109, 995

(1978): Pereyo-Torrellas N, Arch Dermatol 114, 1097

Vesiculobullous eruption 

(1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 186 (passim)

(1988): Laing VB+, J Am Acad Dermatol 19, 91 (passim)

Wound complications 

(1988): Proper SA+, J Am Acad Dermatol 18, 1173

Alopecia / hair loss <1%

(1985): J Rheumatol 12, 13

(1979): Meyer HC, JAMA 242, 142

Hair disorder 

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

Nail changes 

(1994): Halpern SM, Arch Dermatol 130, 259 (passim)

Onycholysis 

(1982): Bailin PL+, Clinics In Rheumatic Diseases WB Saunders 8, 493

Gingival ulceration <1%

(package insert)

Nasal congestion 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3975% (with famotidine)

Oral lesions 

(1974): Regalado RG+, J Int Med Res 2, 115

Oral mucosal irritation 

(2020): Ioroi T+, J Pharm Health Care Sci 6, 12

Xerostomia (dry mouth) <1%

(package insert)

Cardiac failure 

(2016): Kontogiorgis C+, Curr Vasc Pharmacol 14(6), 502 [REVIEW]

Cardiotoxicity 

(2016): Prescrire Int 25(167), 14 [REVIEW] (high-dose)

(2015): Richette P+, Expert Opin Drug Saf 14(8), 1259 [REVIEW]

Hypertension 

(2015): Bello AE+, Curr Med Res Opin 31(3), 407 (3 cases) (with famotidine)

(2015): Bello AE+, Curr Med Res Opin 31(3), 3979% (with famotidine)

(2012): Aljadhey H+, BMC Cardiovasc Disord 12

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3273% (with famotidine)

Kounis syndrome / allergic angina syndrome / allergic myocardial infarction 

(2017): Akcay M, Anatol J Cardiol 18(5), 380

(2012): Alves MF+, Int J Cardiol 158(2), 41

(2010): Gazquez V+, J Investig Allergol Clin Immunol 20 (2), 162

(2009): Kumar A+, Int J Cardiol 137 (3), e79

Aseptic meningitis 

(2020): Bianchi L+, Contact Dermatitis Feb, Epub ahead of print (1 case)

(2019): Desgranges F+, BMJ Case Rep 12(11), e231619 (1 case)

(2016): Andres-del Olmo B+, Med Clin (Barc) (Spanish) 146(3), 140

(2011): Moreno-Ancillo A+, J Investig Allergol Clin Immunol 21(6), 484

(2010): Sepcic J+, Coll Antropol 34 (3), 1101 (with ranitidine and ciprofloxacin)

(2006): Cano Vargas-Machuca E+, Rev Neurol (Spanish) 42(4), 217

(2006): Rodriguez SC+, Medicine (Baltimore) 85(4), 214 [REVIEW] (2 cases)

(2004): Hidalgo Natera A+, Med Clin (Barc) 122(17), 678

(2004): Nguyen HT+, Ann Pharmacother 38(3), 408

(2002): Lee RZ+, Rheumatology (Oxford) 41(3), 353

(1999): Pisani E+, Ital J Neurol Sci 20(1), 59

(1997): Horn AC+, Ann Pharmacother 31(9), 10091 case

(1993): Colamarino R+, Therapie 48(5), 516

(1989): Gilbert GJ+, South Med J 82(4), 514

(1987): Jensen S+, Acta Med Scand 221(5), 509

(1983): Treves R+, Rev Rhum Mal Osteoartic 50(1), 75

(1982): Hoffman M+, Clin Rheumatol 1(2), 128 (1 case)

(1980): Giansiracusa DF+, Arch Intern Med 140(11), 1553

(1979): Samuelson CO Jr+, West J Med 131(1), 57

(1978): Widener HL+, JAMA 239(11), 1062

Depression 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3974% (with famotidine)

Fever (pyrexia) 

(2006): Gonzalo-Garijo MA+, J Investig Allergol Clin Immunol 16(4), 266

Forehead swelling 

(2020): Chopra A+, J Indian Soc Periodontol 24(2), 178 (1 case)

Headache 

(2018): Lewis F+, Clin Pharmacol Drug Dev Jan, Epub ahead of print (2 cases) (from topical)

(2015): Bello AE+, Curr Med Res Opin 31(3), 3974% (with famotidine)

(2014): Cossu MV+, Drug Des Devel Ther 8, 411 (with isosorbide dinitrate)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3273% (with famotidine)

Hypothermia 

(2016): Donati M+, Eur J Clin Pharmacol 72(10), 1239Pediatric

Paresthesias 

(2018): Lewis F+, Clin Pharmacol Drug Dev Jan, Epub ahead of print (1 case) (from topical)

Somnolence (drowsiness) 

(2017): Poonai N+, CMAJ 189(40), e125222%Pediatric

(2015): Au AH+, PLoS One 10(6), Epub [REVIEW]13% (with oxycodone)

Gynecomastia <1%

(package insert)

Hyperkalemia 

(2013): Platts-Mills TF+, Am J Emerg Med 31(2), 465.e1 (life threatening)Fatal

Hypokalemia 

(2017): Bichard L+, Intern Med J 47(6), 707 (with codeine)

Pseudoporphyria 

(2000): De Silva B+, Pediatr Dermatol 17, 480

(1992): Petersen CS+, Ugeskr Laeger (Danish) 154, 1713

Abdominal distension 

(2015): Bello AE+, Curr Med Res Opin 31(3), 39712% (with famotidine)

Abdominal pain 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3974% (with famotidine)

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3275% (with famotidine)

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 138

(1993): Morgan GJ+, Am J Med 95(2A), 19S9%Geriatric

Constipation 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3975% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3274% (with famotidine)

(2011): White PF+, Anesth Analg 112(2), 3237%

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 138

Diarrhea 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3979% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3275% (with famotidine)

(1993): Eversmeyer W+, Am J Med 95(2A), 10S

(1993): Morgan GJ+, Am J Med 95(2A), 19S1%Geriatric

Dyspepsia / functional dyspepsia / gastroparesis 

(2015): Bello AE+, Curr Med Res Opin 31(3), 39712% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3275% (with famotidine)

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 138

(1993): Eversmeyer W+, Am J Med 95(2A), 10S

Flatulence 

(2015): Bello AE+, Curr Med Res Opin 31(3), 39711% (with famotidine)

Gastroenteritis 

(2015): Bello AE+, Curr Med Res Opin 31(3), 397 (with famotidine)

Gastroesophageal reflux 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3975% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (exacerbation / with famotidine)

Gastrointestinal bleeding 

(2015): Tandon VR+, Indian J Med Res 142(1), 33

(2012): Sarici SU+, Eur Rev Med Pharmacol Sci 16(3), 325

Gastrointestinal disorder / discomfort 

(2019): Kyeremateng K+, Curr Med Res Opin Apr, Epub ahead of print

(2013): Bianciotto M+, Arch Dis Child 98(3), 218Pediatric

(2012): Van Wijck K+, Med Sci Sports Exerc 44(12), 2257

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI) 

(2021): Gui MZ+, Transl Pediatr 10(6), 1737-1742 (1 case / female)Pediatric

(2020): Zoubek ME+, Aliment Pharmacol Ther 51(6), 603-611 [REVIEW] (22 cases)

(2017): Zoubek ME+, Clin Gastroenterol Hepatol Aug, Epub ahead of print

(2016): Donati M+, Br J Clin Pharmacol 82(1), 238

(2007): Autret-Leca E+, Therapie 62(2), 173Pediatric

Nausea 

(2018): Playne R+, Paediatr Anaesth Oct, Epub ahead of print (with paracetamol)

(2015): Bello AE+, Curr Med Res Opin 31(3), 3979% (with famotidine)

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3276% (with famotidine)

(2011): Mallen SR+, Curr Med Res Opin 27(7), 1359

(2010): Khwaja SM+, CJEM 12(1), 39

(2005): Litkowski LJ+, Clin Ther 27(4), 418 (with oxycodone)

(2005): Yilmaz H+, Turk J Gastroenterol 16(3), 1383%

Pancreatitis / acute pancreatitis 

(2016): Moslim MA+, Am J Ther 23(6), e1918

(2006): Magill P+, JOP 7(3), 311 (overdose)

Vanishing bile duct syndrome 

(2018): Xie W+, BMC Gastroenterol 18(1) (1 case)

(2014): Kim HY+, Yonsei Med J 55(3), 834Pediatric

(2004): Taghian M+, J Pediatr 145(2), 273 [REVIEW]

Vomiting  

(2018): Playne R+, Paediatr Anaesth Oct, Epub ahead of print (with paracetamol)

(2015): Bello AE+, Curr Med Res Opin 31(3), 3974% (with famotidine)

(2015): Tajti J+, Expert Opin Drug Saf 14(6), 891

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

(2006): Prado J+, Sao Paulo Med J 124(3), 135Pediatric

(2005): Litkowski LJ+, Clin Ther 27(4), 418 (with oxycodone)

Urinary tract infection 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3979% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Anemia 

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Hemolytic uremic syndrome 

(2007): Schoenmaker NJ+, Clin Nephrol 68(3), 177 (1 case)

Thrombocytopenia 

(2017): Olgun H+, Pediatr Neonatol 58(1), 29

(2014): Curtis BR, Immunohematology 30(2), 55 [REVIEW]

(2014): Ferrajolo C+, Expert Opin Drug Saf 13 Suppl 1, 9Pediatric

(2014): Ranieri MM+, Pharmacotherapy 34(2), e14

(2010): Reese JA+, Blood 116(12), 2127

Arthralgia 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3976% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3271% (with famotidine)

Back pain 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3975% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Dystonia 

(2015): Zadori D+, Expert Opin Drug Saf 14(6), 877 [REVIEW]

Rhabdomyolysis 

(2007): Nelson H+, Pharmacotherapy 27(4), 608 (overdose)

(1997): Ramachandran S+, BMJ 1997 May 31; 314(7094), 1593 (with ciprofibrate)

(1989): Menzies DG+, Med Toxicol Adverse 4(6), 468

Amblyopia 

(1972): Palmer CA, Br Med J 3(5829), 765

(1972): Thompson M, Br Med J 4(5839), 550

Optic neuritis 

(2012): Finsterer J+, Arq Neuropsiquiatr 70(10), 829

(2006): Gamulescu MA+, Ann Pharmacother 40(3), 571

Periorbital edema 

(2010): Balas M+, Am J Health Syst Pharm 67(11), 906Geriatric

(2005): Palungwachira P+, J Dermatol 32(12), 969

(1979): Finch WR+, JAMA 241, 2616

Visual disturbances 

(1989): Nicastro NJ, Ann Ophthalmol 21(12), 447

(1981): Tullio CJ, Am J Hosp Pharm 38(9), 1362

Hearing loss (hypoacusis) 

(2012): Curhan SG+, Am J Epidemiol 176(6), 544

(2010): Sepcic J+, Coll Antropol 34 (3), 1101 (with ranitidine and ciprofloxacin)

Tinnitus 

(2010): Sepcic J+, Coll Antropol 34 (3), 1101 (with ranitidine and ciprofloxacin)

(1998): Davison SP+, Ear Nose Throat J 77(10), 820

Vestibular disorder 

(2010): Sepcic J+, Coll Antropol 34 (3), 1101 (with ranitidine and ciprofloxacin)

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury 

(2017): Bichard L+, Intern Med J 47(6), 707 (with codeine)

(2017): Olgun H+, Pediatr Neonatol 58(1), 29

(2014): Yue Z+, Eur J Clin Pharmacol 70(4), 479Pediatric (with acetaminophen)

(2010): Dixit M+, Pharmaceuticals (Basel) 3(4), 1279 [REVIEW]

Bronchitis 

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Cough 

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Influenza 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3975% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Nasopharyngitis 

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Pharyngolaryngeal pain 

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Pulmonary embolism 

(2016): Bilora F+, Aging Clin Exp Res 28(1), 167 (life threatening)Fatal (high-dose)

Pulmonary Infiltration with Eosinophilia (PIE) syndrome 

(1992): Goodwin SD+, Arch Intern Med 152(7), 1521 [REVIEW] (4 cases)

Rhinitis 

(2015): Tandon VR+, Indian J Med Res 142(1), 33

Sinusitis 

(2015): Bello AE+, Curr Med Res Opin 31(3), 39711% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3272% (with famotidine)

Upper respiratory tract infection 

(2015): Bello AE+, Curr Med Res Opin 31(3), 3978% (with famotidine)

(2012): Bello AE, Ther Adv Musculoskelet Dis 4(5), 3274% (with famotidine)

Adverse effects 

(2016): Carnovale C+, Expert Opin Drug Saf 15(sup2), 35 [REVIEW]Pediatric

(2016): Hartling L+, Pain Res Manag Dec, Epub [REVIEW]Pediatric

(2016): Kaguelidou F+, Br J Clin Pharmacol 82(4), 1058Pediatric

(2016): Rafaniello C+, Pharmacol Res 104, 108 (gastrointestinal)

(2016): Saint-Martin C+, Therapie (French) 71(5), 467Pediatric

(2014): Lee WJ+, Pharmacotherapy 34(9), 91872%Pediatric

(2014): Pellicano R, Minerva Gastroenterol Dietol 60(4), 255 [REVIEW] (gastrointestinal)

(2013): Shrivastava MP+, J Indian Med Assoc 111(2), 9951%

(2012): Chaudhry T+, Intern Med J 42(6), 66535%

(2011): Chang CH+, Pharmacoepidemiol Drug Saf 20(7), 763 (gastrointestinal)

(2009): Kuptniratsaikul V+, J Altern Complement Med 15(8), 89144%

(2004): Shi W+, Acta Pharmacol Sin 25(3), 357

(2003): Shi W+, Zhonghua Liu Xing Bing Xue Za Zhi (Chinese) 24(11), 1044 [REVIEW]17%

Death 

(2001): Stevenson R+, Scott Med J 46(3), 84

Side effects 

(2006): Evers S+, Neurology 67(3), 497 (mild)Pediatric



Adverse reactions attributed to entire drug class Non-steroidal anti-inflammatory (NSAID)

Angioedema 

(2017): Dona I+, Allergy 72(9), 1346

(2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143

DRESS syndrome 

(2017): Matta JM+, An Bras Dermatol 92(1), 30 [REVIEW] (passim)

Exanthems 

(2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 539%

Fixed eruption 

(2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 5316%

Hypersensitivity 

(2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143 [REVIEW]

(2010): Um SJ+, J Investig Allergol Clin Immunol 20(7), 55613%

Lupus erythematosus 

(2012): Dalle Vedove C+, J Dtsch Dermatol Ges 10(12), 889 [REVIEW]

Photosensitivity 

(2017): Lugovic-Mihic L+, Acta Clin Croat 56(2), 277 [REVIEW]

(2016): Zuba EB+, Acta Dermatovenerol Croat 24(1), 55 [REVIEW]

Rash 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Stevens-Johnson syndrome 

(2011): Barvaliya M+, J Postgrad Med 57(2), 11522%

(2011): Ferrandiz-Pulido C+, Med Clin (Barc) 136(13), 583

(2011): Singalavanija S+, J Med Assoc Thai 94 Suppl 3, S855%

Toxic epidermal necrolysis (Lyell's syndrome) 

(2011): Barvaliya M+, J Postgrad Med 57(2), 11522%

(2011): Ferrandiz-Pulido C+, Med Clin (Barc) 136(13), 583

Urticaria / hives 

(2017): Dona I+, Allergy 72(9), 1346

(2015): Farshchian M+, Clin Cosmet Investig Dermatol 8, 5327%

(2014): Dona I+, J Investig Allergol Clin Immunol 24(3), 143

Cardiotoxicity 

(2018): Wongrakpanich S+, Aging Dis 9(1), 143 [REVIEW]

(2017): Varga Z+, Cureus 9(4), e1144 [REVIEW]

Hypertension 

(2017): Varga Z+, Cureus 9(4), e1144 [REVIEW]

(2015): Richette P+, Expert Opin Drug Saf 14(8), 1259 [REVIEW]

Headache 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Vertigo / dizziness 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Abdominal pain 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Constipation 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Diarrhea 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

(2015): Koffeman AR+, Scand J Prim Health Care 33(3), 1638%

Dyspepsia / functional dyspepsia / gastroparesis 

(2017): Yang M+, Curr Med Res Opin 33(6), 973 [REVIEW]

(2015): Koffeman AR+, Scand J Prim Health Care 33(3)_, 16334%

Gastric obstruction 

(2017): Yang M+, Curr Med Res Opin 33(6), 973 [REVIEW]

Gastrointestinal adverse reaction 

(2021): McEvoy L+, Front Pharmacol Jun, eCollection [REVIEW]

Gastrointestinal bleeding 

(2018): Chi TY+, Medicine (Baltimore) 97(18), e0665

(2018): Wongrakpanich S+, Aging Dis 9(1), 143 [REVIEW]

(2017): Yang M+, Curr Med Res Opin 33(6), 973 [REVIEW]

(2016): Cardile S+, World J Gastroenterol 22(5), 1877Pediatric

(2016): Venerito M+, Pharmaceuticals (Basel) 3(7), 2225 [REVIEW]

Gastrointestinal ulceration 

(2017): Chinese Rheumatism Data Center, Zhonghua Nei Ke Za Zhi (Chinese) 56(1), 81

Nausea 

(2017): Eccleston C+, Cochrane Database Syst Rev 8, CD012537 [REVIEW]Pediatric

Peptic ulceration 

(2013): Sinha M+, Mediators Inflamm Mar, Epub [REVIEW]

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury 

(2018): Wongrakpanich S+, Aging Dis 9(1), 143 [REVIEW]

(2016): Vuckovic S+, Curr Med Chem 23(19), 1953

(2015): Jung JH+, BMC Res Notes 8(1), 793

(2015): Richette P+, Expert Opin Drug Saf 14(8), 1259 [REVIEW]

Dyspnea / shortness of breath 

(2015): Koffeman AR+, Scand J Prim Health Care 33(3), 1638%

Adverse effects 

(2016): Gerosa M+, Expert Opin Pharmacother 17(11), 1539 [REVIEW] (in pregnancy)

(2016): Walters KM+, Immunol Allergy Clin North Am 36(4), 625 [REVIEW]

(2016): Wong YJ, Evid Based Dent 17(3), 83 [REVIEW]3–44%

(2015): Drago F+, Int J Clin Pharm 37(5), 739 (cutaneous)

(2015): Richette P+, Expert Opin Drug Saf 14(8), 1259 [REVIEW] (gastrointestinal)

(2015): Tian XY+, Arch Dermatol Res 307(9), 82919% (cutaneous)

(2014): Carter GT+, Phys Med Rehabil Clin N Am 25(2), 457 [REVIEW]

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top